You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Merck
Colorcon
Medtronic
McKesson

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Desipramine hydrochloride - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for desipramine hydrochloride and what is the scope of patent protection?

Desipramine hydrochloride is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Amneal Pharms Co, Ani Pharms Inc, Heritage Pharms Inc, Novast Labs, Sandoz, Usl Pharma, and Us Pharm Holdings, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for desipramine hydrochloride. Nine suppliers are listed for this compound.

Recent Clinical Trials for desipramine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 4
Stanford UniversityPhase 4
State University of New York at BuffaloPhase 4

See all desipramine hydrochloride clinical trials

Recent Litigation for desipramine hydrochloride

Identify potential future generic entrants

District Court Litigation
Case NameDate
SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.2017-07-06

See all desipramine hydrochloride litigation

Pharmacology for desipramine hydrochloride
Medical Subject Heading (MeSH) Categories for desipramine hydrochloride
Synonyms for desipramine hydrochloride
10-11-Dihydro-N-methyl-5H-dibenz(Z)[b,f]azepine-5-propanamine hydrochloride
10,11-Dihydro-5-(3-(methylamino)prop-yl)-5h-dibenz(b,f)azepine hydro-chloride
10,11-Dihydro-5-(3-(methylamino)propyl)-5H-dibenz(b,f)azepine hydrochloride
10,11-Dihydro-5-(3-(methylamino)propyl)-5H-dibenz(b,f)azepine monohydrochloride
10,11-Dihydro-N-methyl-5H-dibenz-[b,f]azepine hydrochloride
10,f]azepine hydrochloride
10,f]azepine monohydrochloride
1Y58DO4MY1
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine hydrochloride
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine hydrochloride
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine hydrochloride
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;hydrochloride
5-(3-Methylaminopropyl)-5H-dibenz[b,f]azepine hydrochloride
50-47-5 (Parent)
58-28-6
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, hydrochloride
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-, monohydrochloride
5H-Dibenz[b, 10,11-dihydro-5-[3-(methylamino)propyl]-, hydrochloride
5H-Dibenz[b, 10,11-dihydro-5-[3-(methylamino)propyl]-, monohydrochloride
5H-Dibenz[b, 10,11-dihydro-N-methyl-, monohydrochloride
AC1L2324
AKOS015994722
AN-083
B7261
BG0162
CAS-58-28-6
CC-26348
CCG-38909
CHEBI:4449
CHEMBL1696
CPD000036827
CS-8201
CTK8F9062
D 3900
D00812
Demethylimipramine hydrochloride
Desimipramine hydrochloride
Desimipramine, hydrochloride
Desipramine Hcl
Desipramine hydrochloride (JAN/USP)
Desipramine hydrochloride [USAN:JAN]
Desipramine hydrochloride [USAN:USP:JAN]
Desipramine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Desipramine hydrochloride solution, drug standard, 1.0 mg/mL in methanol
Desipramine hydrochloride, >=98% (TLC), powder
Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Desipramine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Desipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Desipramine monohydrochloride
Desiprimine
Desmethylimipramine chloride
Desmethylimipramine hydrochloride
Desmethylimipramine monohydrochloride
Desmethylimipramine-hydrochloride
Despiramine hydrochloride
DMI hydrochloride
DSSTox_CID_26942
DSSTox_GSID_46942
DSSTox_RID_82024
DTXSID9046942
EINECS 200-373-1
Epitope ID:224551
EU-0100358
EX 4355
EX-4355
FT-0603109
G 35020
G-35020
GMI
HMS1569E07
HMS1920C22
HY-B1272
Imipraminedemethyl hydrochloride
iren
JB 8181
JB-8181
KS-1296
LP00358
LS-60422
MFCD00058108
MLS000028418
MLS000038088
MLS001056757
MLS002222246
MLS002548871
MolPort-000-917-727
N-(.gamma.-Methylaminopropyl)iminodibenzyl hydrochloride
N-(gamma-Methylaminopropyl)iminodibenzyl hydrochloride
NC00681
NCGC00015340-02
NCGC00015340-14
NCGC00093794-01
NCGC00093794-02
NCGC00093794-03
NCGC00093794-04
NCGC00093794-05
NCGC00261043-01
Norpolake
Norpramin
Norpramin (TN)
Nortimil
NSC 114901
NSC-114901
NSC-756719
NSC114901
NSC756719
Opera_ID_943
Pertofran
Pertofrane
Pertofrin
Pertrofan
Petylyl
Pharmakon1600-01500227
Prestwick_706
REGID_for_CID_65327
RMI 9,384A
RMI-9384A
SAM002264605
SC-57976
SCHEMBL41992
SMR000036827
SPECTRUM1500227
SR-01000003060
SR-01000003060-2
SR-01000003060-8
Tox21_110129
Tox21_110129_1
Tox21_500358
UNII-1Y58DO4MY1
VA10690
WLN: T C676 BN&T&J B3M1 &GH
XAEWZDYWZHIUCT-UHFFFAOYSA-N

US Patents and Regulatory Information for desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 072100-001 May 24, 1988 AB RX No No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 205153-006 Oct 28, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Actavis Totowa DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 074430-002 Feb 9, 1996 AB RX No No   Start Trial   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Novast Labs DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 204963-004 Dec 26, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 205153-003 Oct 28, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for desipramine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Sanofi Aventis Us PERTOFRANE desipramine hydrochloride CAPSULE;ORAL 013621-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Express Scripts
Johnson and Johnson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.